Targeting pathways involved in oxidative stress and fibrosis, such as TXNIP, SNAI1, and related signaling pathways, can provide new therapeutic approaches in managing elevated IOP and mitigating glaucoma progression in diabetic patients. This evidence concerns the gene SNAI1 and glaucoma.